{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chickenpox/prescribing-information/chlorphenamine/","result":{"pageContext":{"chapter":{"id":"a2d64426-afb7-5590-998d-3ed0d13b78d2","slug":"chlorphenamine","fullItemName":"Chlorphenamine","depth":2,"htmlHeader":"<!-- begin field b985db26-bd98-4c2c-a192-d9b2a109fecd --><h2>Chlorphenamine</h2><!-- end field b985db26-bd98-4c2c-a192-d9b2a109fecd -->","summary":"","htmlStringContent":"<!-- begin item 844849cc-2d03-4d98-a5a3-b8f7f8b70a9e --><!-- end item 844849cc-2d03-4d98-a5a3-b8f7f8b70a9e -->","topic":{"id":"5d1b7a44-f7ff-52e9-a218-c53ecadb0e4c","topicId":"4960f8a4-0140-4c3b-9bd0-b1ac6fccd648","topicName":"Chickenpox","slug":"chickenpox","lastRevised":"Last revised in August 2018","chapters":[{"id":"fe0450ab-ddfd-5960-bb47-b986d9cc6059","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ff90f80f-13d4-5732-8d09-9c5566ce6ec2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"16ae9969-1384-5b7b-aff0-1ac19aeee530","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"10059b43-4a23-59cf-8f5f-31f8d5e8e3c9","slug":"changes","fullItemName":"Changes"},{"id":"5f0098ae-9d37-5658-9379-66477733f220","slug":"update","fullItemName":"Update"}]},{"id":"9d70228e-0283-5d34-a4af-5237097d0a02","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fa1d46ea-9d63-5d1a-b60c-9b96e87f802c","slug":"goals","fullItemName":"Goals"},{"id":"4e21e939-92fd-555c-a175-93b8a626169a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ea18d1e8-0bdd-542f-a985-2952ecabca2d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5d911096-5b50-551b-a17a-cff3070315b0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"601f7c68-386e-5474-96f1-d6239bd81750","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"305e8fa8-8eb6-5b69-a902-93019e0c2c17","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"bb9b11dc-3295-5e2b-9798-37bb8b6ebbc0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"145f102c-4e0f-52c9-8b3b-e0b5c6eb112e","slug":"definition","fullItemName":"Definition"},{"id":"9f4d0cad-78a8-568f-831e-8878d2f4bfd3","slug":"transmission","fullItemName":"Transmission"},{"id":"5691920a-f618-5a98-ab32-417dfc782db1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"eb6a66b5-2006-5968-a97d-52de72842cbf","slug":"complications","fullItemName":"Complications"}]},{"id":"a3eb8e9b-cdd9-5243-8353-09aac3fdc322","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ff9f70a8-0c29-5357-946d-bbca67eafbbf","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b651c5b4-34df-5480-b05d-909c9023a7a5","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3844af91-e26b-515e-a645-9725d2f54810","fullItemName":"Management","slug":"management","subChapters":[{"id":"7700c175-994a-51d5-a2d0-36eb7478e2c1","slug":"child-or-adult","fullItemName":"Scenario: Child or adult"},{"id":"f6a62aa2-354d-5eee-a868-fb5d162115ef","slug":"pregnant-woman","fullItemName":"Scenario: Pregnant woman"},{"id":"c659257f-8875-5440-ae24-57c071cf226c","slug":"breastfeeding-woman","fullItemName":"Scenario: Breastfeeding woman"},{"id":"499e6045-af39-5bc4-952b-edcb6b29144f","slug":"neonate","fullItemName":"Scenario: Neonate"},{"id":"dac00668-b032-569c-8b5a-260c2f1625b3","slug":"immunocompromised","fullItemName":"Scenario: Immunocompromised"},{"id":"072ae3a5-9cf4-5233-bca1-2d46e53de42b","slug":"exposure-to-chickenpox","fullItemName":"Scenario: Exposure to chickenpox"}]},{"id":"fa12b54d-0c95-5ee8-8884-219ac7a9dd2a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a2d64426-afb7-5590-998d-3ed0d13b78d2","slug":"chlorphenamine","fullItemName":"Chlorphenamine"},{"id":"17d5cf92-3449-52d5-932c-f1b770061787","slug":"aciclovir","fullItemName":"Aciclovir"}]},{"id":"95550d9e-6be2-5a94-924a-c4c2f8e7dbe4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"880099bb-bff8-543e-a1e8-267413ef45b9","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c80905f1-b771-5170-8be8-c1bcee935552","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6bf66548-b486-53e1-bce7-d9bb45af9bea","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"52168b40-dab0-5afb-9662-bb28014b5734","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5fa2da47-e83a-5886-9c1b-c6ae4e97a0a7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"769ea126-78ac-540c-a1c9-38446d44e22e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"87e1772a-0cd8-5e0c-ad7a-b676a65171bb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"fa12b54d-0c95-5ee8-8884-219ac7a9dd2a","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"272f8110-97d6-5552-bf7c-5965d2e99fce","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 8e2c3040-ff7c-4276-b9c6-39c807afeda3 --><h3>Dose</h3><!-- end field 8e2c3040-ff7c-4276-b9c6-39c807afeda3 -->","summary":"","htmlStringContent":"<!-- begin item f5e00d17-159f-410a-bf2a-2c49620a6068 --><!-- begin field cf353a17-52b3-4cb6-80e5-a6347b0b7461 --><ul><li>For children aged:<ul><li>Less than 1 year — chlorphenamine is not recommended as it is not licensed in this group.</li><li>1–2 years: give 1 mg twice daily. </li><li>2–6 years: give 1 mg every 4–6 hours (maximum 6 mg daily).</li><li>6–12 years: give 2 mg every 4–6 hours (maximum 12 mg daily).</li><li>12–18 years: give 4 mg every 4–6 hours (maximum 24 mg daily).</li></ul></li><li>For adults: <ul><li>Give 4 mg every 4–6 hours (maximum 24 mg daily). If the person is elderly, reduce the dose to a maximum of 12 mg daily.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">BNF for Children, 2017</a>]</p><!-- end field cf353a17-52b3-4cb6-80e5-a6347b0b7461 --><!-- end item f5e00d17-159f-410a-bf2a-2c49620a6068 -->","subChapters":[]},{"id":"f71c549c-5b7e-5e07-be95-ca7aa94ea6c5","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 30461aa4-d6c4-4934-b5af-f2e25356c5bb --><h3>Adverse effects</h3><!-- end field 30461aa4-d6c4-4934-b5af-f2e25356c5bb -->","summary":"","htmlStringContent":"<!-- begin item 0dff93fd-8208-49ed-82fc-92008f622302 --><!-- begin field ee0003e0-6796-48f6-8fd3-ab497fb0423b --><ul><li><strong>Adverse effects of chlorphenamine include:</strong><ul><li>Neurological — dizziness, restlessness, psychomotor impairment, headaches, sedation.</li><li>Anticholinergic effects — blurred vision, dry mouth, and urinary retention.</li><li>Skin — urticaria, rash, exfoliative dermatitis, photosensitivity.</li><li>Gastrointestinal — nausea, vomiting, abdominal pain, diarrhoea, dyspepsia.</li><li>Cardiovascular — palpitations, tachycardia, arrhythmias.</li><li>Neuropsychiatric — depressed mood, excitation, irritability, nightmares, confusion (more common in children and older people).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">ABPI, 2016d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">BNF 72, 2016</a>]</p><!-- end field ee0003e0-6796-48f6-8fd3-ab497fb0423b --><!-- end item 0dff93fd-8208-49ed-82fc-92008f622302 -->","subChapters":[]},{"id":"5b79e08a-b8e5-5805-b87f-18a489770427","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field a676b232-0891-4efd-b1b5-e35ac070a0f6 --><h3>Contraindications and cautions</h3><!-- end field a676b232-0891-4efd-b1b5-e35ac070a0f6 -->","summary":"","htmlStringContent":"<!-- begin item b1b8b4c2-1801-40db-8371-8ce696a2fbf2 --><!-- begin field f3e0e27a-e100-4e55-8688-ca98ef86628f --><ul><li><strong>Do not give chlorphenamine</strong> if the person has had a monoamine oxidase inhibitor (MAOI) within the last 2 weeks — the anticholinergic effects of chlorphenamine are intensified by MAOIs.</li><li><strong>Chlorphenamine should be used with caution in people with:</strong><ul><li>Hepatic impairment — avoid sedating antihistamines in severe liver disease.</li><li>Renal impairment.</li><li>Prostatic hypertrophy.</li><li>Urinary retention.</li></ul><ul><li>Severe hypertension or cardiovascular disease.</li><li>Raised intraocular pressure or glaucoma.</li><li>Pyloroduodenal obstruction.</li><li>Epilepsy </li><li>Asthma, bronchitis, or bronchiectasis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">ABPI, 2016d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">BNF 72, 2016</a>]</p><!-- end field f3e0e27a-e100-4e55-8688-ca98ef86628f --><!-- end item b1b8b4c2-1801-40db-8371-8ce696a2fbf2 -->","subChapters":[]},{"id":"0cb5a000-ee8d-5b92-9353-03317705db91","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field debf9585-ceee-40bc-b548-f79095645f8a --><h3>Drug interactions</h3><!-- end field debf9585-ceee-40bc-b548-f79095645f8a -->","summary":"","htmlStringContent":"<!-- begin item 1e07de8e-a2ba-45d7-9a20-60ef62828af0 --><!-- begin field 54697291-7c38-4444-9705-5faf16f2c1dc --><ul><li><strong>Possible drug interactions requiring caution include:</strong><ul><li>Hypnotics, anxiolytics, and opioids — may cause an increase in sedative effects.</li><li>Phenytoin — chlorphenamine inhibits phenytoin metabolism and can lead to phenytoin toxicity.</li><li>MAOIs — do not give chlorphenamine if the person has had a monoamine oxidase inhibitor (MAOI) within the last 2 weeks because the anticholinergic effects of chlorphenamine are intensified by MAOIs.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">ABPI, 2016d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">BNF 72, 2016</a>]</p><!-- end field 54697291-7c38-4444-9705-5faf16f2c1dc --><!-- end item 1e07de8e-a2ba-45d7-9a20-60ef62828af0 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}